However, as early as 6 months, teriparatide overcomes the inhibition of bone remodelling induced by prior antiresorptive therapy. Previous studies investigated the changes in various

biochemical markers of bone turnover during Selleck P505-15 treatment with teriparatide or PTH(1-84) in osteoporosis treatment-naïve subjects. They reported significant increases in bone formation markers as early as 1 month after starting teriparatide or PTH(1-84) therapy in postmenopausal women with osteoporosis [11, 13, 14, 29–31], in patients with glucocorticoid-induced osteoporosis [10, 32], and in men with idiopathic and hypogonadal osteoporosis receiving teriparatide [17, 33, 34]. The changes in PINP, b-ALP and t-ALP during the first 6 months of teriparatide treatment GF120918 clinical trial in the present study are consistent with those reported previously in treatment-naïve subjects. Several reports have shown that the increase in bone formation markers induced by teriparatide or PTH(1-84) is smaller or shows a delay in subjects GDC-0449 nmr who have been previously treated with a potent bisphosphonate

[16, 17, 19]. This effect is even more marked if the patients are receiving concomitant treatment with potent antiresorptives [15, 19]. However, the delayed effect on bone formation markers observed during the first months of teriparatide or PTH(1-84) therapy is overcome with longer treatment duration, and the differences between treatment-naïve Ibrutinib patients and prior antiresorptive drugs users are no longer statistically significant after 6 months of treatment. Our results are consistent with other studies that compared the effects of different types of antiresorptive drugs on the response

of biochemical markers of bone turnover during teriparatide treatment. During the first 5 months of teriparatide therapy, postmenopausal women with osteoporosis previously treated with risedronate for a minimum of 24 months experienced a statistically significant greater increase in bone marker turnover than patients previously treated with alendronate, but the difference was no longer significant after 6 and 12 months of continuous treatment [35]. Our bone marker and BMD results confirm that long-term teriparatide treatment is able to reverse the low bone turnover status induced by treatment with potent bisphosphonates. This can also be observed at the tissue level with the described changes in microdamage accumulation and dynamic histomorphometric parameters in humans [36–38]. We analyzed the performance of three bone formation markers to monitor teriparatide treatment by evaluating the signal-to-noise ratio.